A Phase I trial of an immunotoxin mixture that targets CD19 and CD22 (Combotox) was performed in children with ALL with a reported CR rate of 21% (3 of 14 evaluable patients) (Herrera et al., 2009). Here, CD19 is linked to acute lymphoblastic leukemia.